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Abstract
Background: Proteins of the tetraspanin family contain four transmembrane domains (TM1-4)
linked by two extracellular loops and a short intracellular loop, and have short intracellular N- and
C-termini. While structure and function analysis of the larger extracellular loop has been
performed, the organization and role of transmembrane domains have not been systematically
assessed.
Results: Among 28 human tetraspanin proteins, the TM1-3 sequences display a distinct heptad
repeat motif (abcdefg)n. In TM1, position a is occupied by structurally conserved bulky residues
and position d contains highly conserved Asn and Gly residues. In TM2, position a is occupied by
conserved small residues (Gly/Ala/Thr), and position d has a conserved Gly and two bulky aliphatic
residues. In TM3, three a positions of the heptad repeat are filled by two leucines and a glutamate/
glutamine residue, and two d positions are occupied by either Phe/Tyr or Val/Ile/Leu residues. No
heptad motif is apparent in TM4 sequences. Mutations of conserved glycines in human CD9 (Gly25
and Gly32 in TM1; Gly67 and Gly74 in TM2) caused aggregation of mutant proteins inside the cell.
Modeling of the TM1-TM2 interface in CD9, using a novel algorithm, predicts tight packing of
conserved bulky residues against conserved Gly residues along the two helices. The homodimeric
interface of CD9 was mapped, by disulfide cross-linking of single-cysteine mutants, to the vicinity
of residues Leu14 and Phe17 in TM1 (positions g and c) and Gly77, Gly80 and Ala81 in TM2
(positions d, g and a, respectively). Mutations of a and d residues in both TM1 and TM2 (Gly25,
Gly32, Gly67 and Gly74), involved in intramolecular TM1-TM2 interaction, also strongly diminished
intermolecular interaction, as assessed by cross-linking of Cys80.
Conclusion: Our results suggest that tetraspanin intra- and intermolecular interactions are
mediated by conserved residues in adjacent, but distinct regions of TM1 and TM2. A key structural
element that defines TM1-TM2 interaction in tetraspanins is the specific packing of bulky residues
against small residues.
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Tetraspanins constitute a large family of integral mem-
brane proteins, characteristically containing 4, 6 or 8 con-
served cysteine residues in the large extracellular loop
(including the CCG and PxxCC motifs), which form
disulfide bonds, and several conserved polar residues in
the intracellular loop and transmembrane regions [1,2].
There are 32 putative tetraspanin family members in
mammals, 37 in Drosophila melanogaster and 20 in
Caenorhabditis elegans. Tetraspanins play diverse roles in
cell adhesion, migration and fusion processes, cellular
activation and signaling (reviewed in refs. [2-4]). Mam-
malian tetraspanins such as CD9, CD63, CD81, CD82,
CD151, rds/peripherin, and uroplakins Ia and Ib have
been most extensively studied, with mouse knock-out
models available for CD9 [5-7], CD81 [8,9], CD151 [10]
and a few others. However, the majority of tetraspanins
are characterized very little, if at all, at genetic, biochemi-
cal or structural levels.
The large extracellular loop (LEL) of tetraspanins has
received most attention, since it contains functionally
important sites. Sequence QRD (194–196) in CD151 is
important for association with integrins, which has func-
tional consequences for integrin-dependent cell spreading
and multicellular cable formation [11]. A site in the LEL
of CD9, SFQ (residues 173–175), is essential for CD9
function in sperm-egg fusion [12]. The crystal structure of
tetraspanin CD81 LEL revealed five α-helixes, A-E [13].
Helices A, B and E form a relatively conserved region in
tetraspanins, whereas the region between helices B and E
is the most variable [14]. Interestingly, the variable region
contains most of the functionally important sites involved
in tetraspanin protein-protein interactions.
A remarkable biochemical property of tetraspanin mole-
cules is their ability to associate with a large number of
other transmembrane proteins, including integrins, mem-
brane-associated growth factors and receptors, MHC class
II molecules, Ig superfamily proteins, and each other
[2,3,15]. Several of these lateral associations of tet-
raspanins are detected in "mild" detergents (Brij series,
CHAPS), but are disrupted by "strong" detergents such as
Triton X-100 or SDS. Multiprotein complexes of tet-
raspanins and associated molecules, also called the "tet-
raspanin web" [16], may represent a distinct tetraspanin-
enriched membrane microdomain [17,18]. The forma-
tion of this microdomain is influenced by palmitoylation
of several conserved juxtamembrane cysteine residues in
tetraspanins [19-21].
The transmembrane domains, encompassing nearly half
of a tetraspanin protein, are the most conserved part of the
molecule (Stipp et al. [1] and this study). However, very
little functional information is available on these
domains. The differential detergent sensitivity of tet-
raspanin-tetraspanin associations suggests that hydropho-
bic interactions between TM helices may play a role.
Indeed, when the large extracellular loop (LEL) of CD151
is deleted, the molecule is still able to associate with other
tetraspanins [22]. Thus, TM domains are strong candi-
dates for mediating tetraspanin-tetraspanin interactions.
The importance of TM domain interactions in intramo-
lecular organization was demonstrated in a study showing
that CD82 fragment TM2-4, lacking TM1, was retained in
the endoplasmic reticulum, but was transported to the cell
surface upon co-expression of TM1 [23]. This in vivo
reconstitution experiment demonstrated a strong interac-
tion between TM1 and the rest of the molecule. Expres-
sion of a truncated CD9 molecule (TM3-LEL-TM4) results
in intracellular accumulation of the protein and signifi-
cant misfolding of the LEL, as judged by inappropriate
disulfide formation and diminished antibody reactivity
(our unpublished data). Similarly, a CD9 epitope in the
LEL is lost in molecules lacking either TM2+TM3 or just
TM4 [24]. Thus, TM domain interactions and packing are
crucial for proper folding, stability and transport of tet-
raspanin molecules.
In a previous study, we showed that covalent cross-linking
of membrane-proximal cysteine residues can be used as a
tool for detection of tetraspanin-tetraspanin associations
[25]. Inhibition of cysteine palmitoylation by 2-
bromopalmitate (2-BP) made cysteines available for
cross-linking and enabled demonstration of specific tet-
raspanin homodimerization and low levels of het-
erodimerization. We concluded that tetraspanin
homodimers, formed in the Golgi, may be a fundamental
structural unit within tetraspanin microdomains.
In this study, we carried out detailed sequence analysis of
human tetraspanin TM domains. We show that a heptad
repeat containing conserved glycine, asparagine and large
hydrophobic residues occurs in TM1 and TM2 domains,
and predict tight intramolecular association of these two
domains by packing of the large residues against the small
residues. Moreover, by using cysteine cross-linking we
map a dimerization interface in the human CD9 protein,
and show that conserved heptad motif glycine residues are
also important for intermolecular CD9 associations.
Results
Sequence analysis of tetraspanin transmembrane domains: 
presence of the heptad repeat motif
We focused our attention on 28 human tetraspanins iden-
tified from the SWISS-PROT and GenBank databases. All
tetraspanins have in common four hydrophobic stretches
(TM domains) of 20–25 residues, and contain highly con-
served residues in the second extracellular loop, inPage 2 of 20
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of the large extracellular loop sequences [14], and dendro-
grams based on full-length alignment can be found in ear-
lier studies [26,27]. The length of each transmembrane
domain was established based on previous sequence anal-
ysis of tetraspanin sequences [27,28], and on annotations
to the database entries. Manual adjustments based on
sequence homology and hydrophobicity profiles were
done to fully delineate the TM domains. The resulting
lengths of TM domains were: TM1 – 23 residues; TM2 – 21
residues; TM3 – 25 residues; TM4 – 25 residues. Two more
residues could be added onto the N-terminal part of TM2;
however, relatively small sequence conservation of these
residues among tetraspanins and occurrence of polar/
charged side chains in some tetraspanins precluded us
from doing so for the global alignment.
Figures 1 and 2 show a multiple sequence alignment of
four TM domains of 28 human tetraspanins. For each
position within the domains, consensus residues were
determined and classified (with individual color code) in
4 categories: 1) large hydrophobic residues (including Val,
Met, Leu, Ile, Phe, Tyr, Trp), 2) small residues (Gly, Ala,
Ser and Thr), 3) Cys, and 4) Asn. When more than two
types of residues occupied a given position in a TM, a
dual-color pattern that reflected the prevalence of the par-
ticular residue type was used (Figure 1). Cysteine residues
were shown separately due to their importance as palmi-
toylation target sites. The highly conserved asparagine res-
idue in TM1 was considered separately. No proline
residues are found in TM domains 1–3 of human
tetraspanins.
An inspection of the multiple sequence alignment reveals
a repeating heptad amino acid pattern, (abcdefg)n, in
TM1, 2 and 3 (Figure 1, 2). Heptad repeats promote heli-
cal coiled coil interactions in multiple soluble and mem-
brane-spanning proteins [29-31]. In the heptad repeat,
hydrophobic residues in positions a and d are of special
importance, as they directly mediate interhelical contacts
by creating a tight knobs-into-holes packing in the coiled
coil structure [32]. For instance, in the leucine zipper of
the yeast transcription factor GCN4, positions a and d
contain Val and Leu residues, respectively, with an Asn
residue in a single a position forming a hydrogen bond
across the GCN4 dimer interface [33].
In TM1 of tetraspanins, highly conserved Asn, Gly and Gly
residues (numbers 18, 25 and 32 in the CD9 sequence)
appear at d positions of the heptad repeats, and residues
14, 21 and 28 are at a positions (Figure 1). In TM2, resi-
dues 67, 74 and 81 (consensus Gly, Gly and Ala, respec-
tively) occupy a positions, whereas residues 63, 70 and 77
are at d positions. Another highly conserved glycine,
Gly80, occupies the 3rd g position in TM2. In TM3, the
conserved pattern consists of two leucine residues (Leu89
and Leu96) and a glutamate/glutamine residue (Glu/
Gln103) in a positions (Figure 2). Two d positions are
also conserved – Phe/Tyr92 and Ile/Val/Leu99. TM4 lacks
a conserved heptad pattern and has only a single con-
served position, Glu/Gln209 (with four exceptions).
These features of TM1-4 of tetraspanins are displayed on
helical wheel diagrams (Figure 3).
Analysis of TM1 sequences
The conserved Asn-Gly-Gly motif, occupying designated d
positions of the heptad repeat, is the most prominent
structural feature of TM1. We also compared sequences of
CD9 orthologs from 10 different organisms (the most
available for any tetraspanin) to gain further insight into
conservation and variability of the TM1 sequence. As
shown in Figure 4, positions a, d and g in TM1 are among
the most conserved (0, 1 and 1 substitution, respectively),
while interspecies variability tends to occur in other posi-
tions: b (5 substitutions), c (4 substitutions), e (4 substi-
tutions) and f (4 substitutions). Thus, the positions
typically involved in coiled coil interactions (a and d) are
the most conserved.
When residues of TM1 are plotted as a helical wheel, addi-
tional structural features are revealed (Figure 3). There are
highly conserved aliphatic and aromatic residues in the
first three a positions of the heptad motif (Phe15, Trp22
and Leu29 in CD9), as well as in g positions (Leu14,
Phe21, Val28 in CD9). The "ridges" formed by these bulky
residues are flanking the "groove"-forming Gly residues of
the Asn-Gly-Gly position d motif. In contrast, b, c, e and f
positions show an overall higher variability among tet-
raspanins, as also seen in the comparison of CD9
orthologs described above.
Analysis of TM2 sequences
A landmark feature of TM2 in tetraspanins is the presence
of highly conserved glycine residues (Gly67, 74, 77 and
80 in CD9, Figure 1). Other substitutions at these posi-
tions are almost exclusively small residues, such as Ala or
Ser. In addition, Ala, Ser or Thr occupy position 81. This
residue, together with Gly67 and Gly74, forms face a of
the helix. Residue Gly77 (position d) is preceded by con-
served, chiefly large hydrophobic residues on the same
helical face (Leu63 and Met70 in CD9). Extremely con-
served Gly80 falls into heptad position g (Figure 3).
Among CD9 orthologs, heptad positions a and d are abso-
lutely conserved, whereas other positions have the follow-
ing number of substitutions: b – 3; c – 2; e – 1; f – 3; g – 1
(Figure 4). Two of the f position residues in TM2 (65 and
79) also show higher variability among different tet-
raspanins (Figures 1, 3). Cysteine residues are frequently
found near the cytoplasmic end of TM2 helix at positions
78 and 79; these cysteines are likely to be palmitoylated.Page 3 of 20
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BMC Structural Biology 2005, 5:11 http://www.biomedcentral.com/1472-6807/5/11Sequence alignment of the transmembrane domains 1 and 2 of 28 human tetraspaninsFig re 1
Sequence alignment of the transmembrane domains 1 and 2 of 28 human tetraspanins. Residues from select posi-
tions of the heptad motifs in TM1 and 2 are highlighted (see text for details). Also highlighted are polar residues and cysteines. 
Consensus residue types are shown by the color scheme indicated. Boxed residues reflect correlated substitutions for position 
pairs 22–74 and 25–70 (details are in the text). The numbers refer to CD9 sequence.
TM1           TM2 
Net1  MMILFNLLIFLCGAALLAVGIWV      FLIAAGVVVFALGFLGCYGAK
CD82  FLFLFNLIFFILGAVILGFGVWI      VFIGVGAVTMLMGFLGCIGAV
CD37  FLFVFNLFFFVLGSLIFCFGIWI      VLAISGIFTMGIALLGCVGAL
CD53  VLFFFNLLFWICGCCILGFGIYL      VFVIVGSIIMVVAFLGCMGSI
Nag2  LMFAFNLLFWLGGCGVLGVGIWL      LLIITGAFVMAIGFVGCLGAI
Net5  MMFLFNLIFWLCGCGLLGVGIWL      LVIAIGTIVMVTGFLGCLGAI
BAB55318 LMFVFNFFIFLGGACLLAIGIWV  ILLAMGGLLFLLGFLGCCGAV
Tsn2  LLLGFNLLFWLAGSAVIAFGLWF      VLVGAGALMMAVGFFGCCGAM
Net4  FIFGFNVIFWFLGITFLGIGLWA      LFLVVGGVMFILGFAGCIGAL
TM4B  LLSLLNGFVAVSGIILVGLGIGG      LCLVMGCITVLLGCAGWYGAT
NM_030927 LLFSYNIIFWLAGVVFLGVGLWA  LVLMVGVVMFTLGFAGCVGAL 
CD151 LLFTYNCCFWLAGLAVMAVGIWT ILVVAGTVVMVTGVLGCCATF
CD81  LLFVFNFVFWLAGGVILGVALWL      ILIAVGAVMMFVGFLGCYGAI
CD9 LLFGFNFIFWLAGIAVLAIGLWL ILIGAGALMMLVGFLGCCGAV
         -----18------25------32---      -----67------74--77--80--
CO-029 SMFTFNFLFWLCGILILALAIWV  ILIAVGAIIMILGFLGCCGAI
Tsn3  VLVFLNLIFWGAAGILCYVGAYV      VIIAVGALLFIIGLIGCCATI
Net2  LLYALNLLFWLMSISVLAVSAWM      VMIAVCCFLIIVGMLGYCGTV
SAS ALCALNVVYMLVSLLLIGVAAWG GVIAVGVFLLLIAVAGLVGAV
Net6  CLCALNLLYTLVSLLLIGIAAWG      VVIAVGIFLFLIALVGLIGAV
CD63  LLYVLLLAFCACAVGLIAVGVGA      VIIAVGVFLFLVAFVGCCGAC
Net7    SLIIYSTVFWLIGALVLSVGIYA ILILLGVVMFMVSFIGVLASL
A15 LLIIYSFVFWITGVILLAVGVWG VLIGTGTTIVVFGLFGCFATC
Tsn6  VLLIYTFIFWITGVILLAVGIWG      VLIATGTVIILLGTFGCFATC
Ocsp     LIFLSNFPFSLLGLLALAIGLWG  GLALGGLVVSAASLAGCLGAL
UPIA     LLVVGNIIILLSGLSLFAETIWV  IAIFCGFSFFMVASFGVGAAL
UPIB     LLIFGNVIIGCCGIALTAECIFF  IGIFVGICLFCLSVLGIVGIM
RDS      GLWLMNWFSVLAGIIIFSLGLFL SLIGMGVLSCVFNSLAGKICY
ROM      GLWLLSWLLALAGGVILLCSGHL AALAAGAVALGTGLVGVGASR
fgabcdefgabcdefgabcdefg      cdefgabcdefgabcdefgab
Consensus
              N G G G G G GA
Consensus color coding:
Large hydrophobic (Leu, Ile, Met, Val, Phe, Tyr, Trp) 
Small (Gly, Ala, Ser, Thr)
Cys    Degree of prevalence
Asn
Individual residues color coding: 
Leu, Ile, Met, Val Gly Cys
Phe,  Tyr, Trp Ala,  Ser, Thr   Asn 
Lys, Arg, His Asp, Glu, GlnPage 4 of 20
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The TM3 domain provides another example of the heptad
repeat pattern. Position a is occupied by two highly con-
served leucine and a glutamate/glutamine residue (Leu89,
Leu96 and Glu/Gln103 in CD9). Furthermore, two d posi-
tions are conserved – Phe/Tyr92 (aromatic residue) and
Ile/Val99 (β-branched aliphatic residue; Figures 2, 3). In
addition, residue 100 in position e is generally Phe or Leu.
Sequence alignment of the transmembrane domains 3 and 4 of 28 human tetraspaninsFig re 2
Sequence alignment of the transmembrane domains 3 and 4 of 28 human tetraspanins. Residues from heptad 
positions a and d in TM3 are highlighted. Also highlighted are the conserved Glu/Gln residue in TM4, other polar residues and 
cysteines. The color scheme is as in Figure 1.
TM3 TM4
Net1     ALVTFFFILLLIFIAEVAAAVVALV  AVTVGGVAAGIGGLELAAMIVSMYL
CD82     LLGLYFAFLLLILIAQVTAGALFYF  LGIILGVGVGVAIIELLGMVLSICL
CD37     LLGLYFGMLLLLFATQITLGILIST  LISIVGICLGVGLLELGFMTLSIFL
CD53     LLMSFFILLLIILLAEVTLAILLFV  FLYIGIITICVCVIEVLGMSFALTL
Nag2     LLLTFFLLLLLVFLLEATIAILFFA  LLAVGIFGLCTALVQILGLTFAMTM
Net5     LLLSFFIVLLVILLAELILLILFFV  KHVLGTVGMCILIMQILGMAFSMTL
BAB55318 LLLFFFLFILIIFLAELSAAILAFI  VYLAGALAIGVLAIELFAMIFAMCL
Tsn2     VLGSFFTCLLVIFAAEVTTGVFAFI  LQLIGIVGIGIAGLTIFGMIFSMVL
Net4     LLKFFSVFLGIIFFLELTAGVLAFV  LTIVAGIFIGIALLQIFGICLAQNL
TM4B     TLLFCILSMVIVLIMEVTAATVVLL  SFTLSGSSLGAAVIQRWGSRYVAQA
NM_030927 LLNFFCGTIVLIFFLELAVAVLAFL  IYIVAGVFIAISLLQIFGIFLARTL
CD151    LLRLYFILLLIIFLLEIIAGILAYA  LRVIGAVGIGIACVQVFGMIFTCCL
CD81     LLGTFFTCLVILFACEVAAGIWGFV  IGIAAIVVAVIMIFEMILSMVLCCG
CD9      MLGLFFGFLLVIFAIEIAAAIWGYS  IIGAVGIGIAVVMIFGMIFSMILCC
         -89--92---96--99---103--------- --------------209----------
CO-029   MLLLFFIGLLLILLLQVATGILGAV  LIIVIGISFGLAVIEILGLVFSMVL
Tsn3     GLATFVIILLLVFVTEVVVVVLGYV  MMHVIWAALAFAAIQLLGMLCACIV
Net2     LLAWYFGSLLVIFCVELACGVWTYE  LQVLRFLGISIGVTQILAMILTITL
SAS      LLFFYMIILGLVFIFQFVISCSCLA  LKILGGVGLFFSFTEILGVWLAMRF
Net6     LLFFYMIILLLVFIVQFSVSCACLA  LRFVGGIGLFFSFTEILGVWLTYRY
Net7     LLQAFMYILGICLIMELIGGVVALT  YTIMAGILLGILLPQFLGVLLTLLY
CD63     LMITFAIFLSLIMLVEVAAAIAGYV  VLVVAAAALGIAFVEVLGIVFACCL
A15      MLKLYAMFLSLVFLAELVAGISGFV  MGIIAGVAFGIAFSQLIGMLLACCL
Tsn6     MLKLYAMFLTLVFLVELVAAIVGFV  MGVVAGISFGVACFQLIGIFLAYCL
Ocsp     LLRGFSGGILAFLVLEAVAGALVVA  LAASGGYAIAVVLLQGAELLLAARL
UPIA     MVLTYLVLMLIVYIFECASCITSYT  YTWGISWFGFAILMWTLPVMLIAMY
UPIB     ILLAYFILMFIVYAFEVASCITAAT  HAWGVAWFGFAILCWTFWVLLGTMF
RDS      WLKPYLAICVLFNIILFLVALCCFL  MNSMGVVTLLIWLFEVTITIGLRYL
ROM      VLGPLLVAGTAGGGGLLVVALGLAL  AGTLGSMLAVTFLLQALVLLGLRYL
gabcdefgabcdefgabcdefgabc
Consensus
L F/Y L  I/V   E/Q E/QPage 5 of 20
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BMC Structural Biology 2005, 5:11 http://www.biomedcentral.com/1472-6807/5/11Among CD9 orthologs, position a has 1 substitution,
positions b, c and f each have 6, positions d and e each
have 2, and g has 4. Thus, as for TM1 and TM2, positions
a and d are among the most conserved, but overall TM3
has more variable positions than TM1 or TM2 (Figure 3).
Less than half of TM3 sequences contain cysteine residues,
and those tend to occur at the internal positions of the
helix (Figure 2).
Helical wheel diagrams of transmembrane domains TM1-4 reflecting the consensus residue typesFigure 3
Helical wheel diagrams of transmembrane domains TM1-4 reflecting the consensus residue types. The color 
scheme is as in Figure 1. The numbers refer to CD9 sequence. Heptad positions a through g are indicated for TM1-3. A pre-
dicted interaction between positions a and e in TM1 and a and d in TM2 is shown by dotted lines (see Figure 6 and text for 
details). Arrows reflect the efficiency of intermolecular cross-linking via single cysteines placed in these positions (see Figure 7 
and text for details).
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BMC Structural Biology 2005, 5:11 http://www.biomedcentral.com/1472-6807/5/11TM4 shows less conservation among various tetraspanin
family members than the other TM domains (Figures 2,
3). The only highly conserved feature is the glutamate/
glutamine residue in position 209. In addition, one or two
cysteine residues can be found at the C-terminal end of
TM4 in some tetraspanins (e.g. CD9, CD81, CD151), and
many sequences contain additional polar residues (Arg,
Lys, His, Asn, Gln). No conserved heptad motif was iden-
tified in TM4, as also confirmed by analysis of substitu-
tions in CD9 orthologs (data not shown).
Mutational analysis of conserved glycine residues in TM1 
and TM2
The conserved nature of the Asn and Gly residues in TM1
and TM2 prompted an analysis of their functional role. To
this end, we have probed whether mutations of these res-
idues destabilize the protein molecule. We expressed a
construct of the first and second TMs of CD9, connected
by the small extracellular loop, and tagged with a C-termi-
nal green fluorescent protein (TM(1+2)-GFP molecule).
In human rhabdomyosarcoma RD cells, the wild-type
fusion protein localized mostly in a reticular, intracellular
pattern, without forming any large aggregates (Figure 5,
panel A). Remarkably, when double mutants Gly25Leu +
Gly32Leu and Gly67Leu + Gly74Leu were expressed, the
protein formed distinct large aggregates in a high propor-
tion of cells (Figure 5, panels C and E). In contrast, double
mutant Gly77Leu + Gly80Leu did not form such aggre-
gates (Figure 5, panel G). Results with respective single
mutants were similar to that with double mutants, with
the aggregation being somewhat more pronounced for
Leu substitutions of Gly67 and Gly74 compared to Gly25
and Gly32 mutations. No aggregation was observed for
Asn18Ser and Asn18Tyr mutants (data not shown). Also,
nearly identical results were obtained with human
HT1080 cells (data not shown).
We interpret these results as an indication that aggregating
mutants are destabilized or misfolded while non-aggre-
gating mutants retain the wild-type conformation.
Intriguingly, mutations to the conserved GG7 motifs
caused protein aggregation while the mutation of other
glycines had no detectable effect. These results also sug-
gest that wild-type GFP, which has weak tendency to self-
associate, could enhance non-specific interactions of
destabilized mutant TM(1+2) CD9 moieties, leading to
their aggregation. Consistent with this hypothesis, the
aggregation of Gly25Leu + Gly32Leu and Gly67Leu +
Gly74Leu double mutants was suppressed when mono-
meric GFP molecule, Leu221Lys [34] was used (Figure 5,
panels D and F). The use of monomeric GFP did not affect
intercellular localization of wild-type CD9 TM(1+2) (Fig-
ure 5, panel B), or a Gly77Leu + Gly80Leu double mutant
(Figure 5, panel H).
In summary, Leu substitutions of Gly residues that are
part of the Asn-Gly-Gly (NGG7) motif in TM1, or Gly-Gly-
Ala (GGA7) motif in TM2, resulted in destabilization and
Sequence alignment of TM1-3 for ten vertebrate orthologs of CD9Fig re 4
Sequence alignment of TM1-3 for ten vertebrate orthologs of CD9. Heptad positions a and d in TM1, TM2 and TM3 
are highlighted in green. Residues that differ between orthologs are shown in yellow.
       TM1       TM2 TM3
      18       25       32 67        74        81     89        96        103        110 
Human      LLFGFNFIFWLAGIAVLAIGLWL  ILIGAGALMMLVGFLGCCGAV  MLGLFFGFLLVIFAIEIAAAIWGYS
Monkey     LLFGFNFIFWLAGIAVLAIGLWL ILIGAGALMMLVGFLGCCGAV  MLGLFFGFLLVIFAIEIAAAIWGYS
Pig        LLFGFNFIFWLAGIAVLAIGLWL  ILIGAGALMMVVGFLGCCGAV  MLGLFFGFLLVIFAIEIPAAIWGYS
Cow        LLFGFNFIFWLAGIAVLSVGLWL  ILIGAGALMMLVGFLGCCGAV  MLGLFFSFLLVIFAIEVAAAIWGYS
Cat        LLFGFNFIFWLAGIAVLAVGLWL  ILIGAGALMMLVGFLGCCGAV  MLGLFFGFLLVIFAIEIAAAIWGYS
Rat        LLFGFNFIFWLAGIAVLAIGLWL  ILIGAGALMMLVGFLGCCGAV  MLGLFFGFLLVIFAIEIAAAVWGYT
Mouse      LLFGFNFIFWLAGIAVLAIGLWL  ILIGAGALMMLVGFLGCCGAV  MLGLFFGFLLVIFAIEIAAAVWGYT
Chicken    LLFGFNFVFWLAGTAVLAIGLWL ILIGAGALMMLVGFLGCCGAL  MLGLFFVFLFVIFALEIATAIWGFA
Lamprey    LLFVFNFVFWLAGGAVLGIALWL VLMGAGALMMLIGFLGCCGAI  MPGSFFVCLLVVFAAEIAAGIWGFL
Zebrafish  SMFLLNSVFWIAGTAVLAVGLWL  ILIAAGALMMVVGFFGCCGAI  MLGLFFFFLLVIFAVEVAAGIWGFS
fgabcdefgabcdefgabcdefg  cdefgabcdefgabcdefgab  gabcdefgabcdefgabcdefgabcPage 7 of 20
(page number not for citation purposes)
BMC Structural Biology 2005, 5:11 http://www.biomedcentral.com/1472-6807/5/11Expression of wild-type and mutant CD9 TM(1+2)-GFP proteins in human cellsFigure 5
Expression of wild-type and mutant CD9 TM(1+2)-GFP proteins in human cells. Human rhabdomyosarcoma RD 
cells were transfected with constructs encoding CD9 TM(1+2)-GFP fusion proteins that carried mutations indicated. Either 
wild-type or monomeric (L221K) GFP was used. Images were captures 18–28 hours post-transfection.Page 8 of 20
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stitutions of Gly77 or Gly80, which are not part of these
motifs (Figure 3), failed to show such aggregation.
Prediction and modelling of interaction between TM1 and 
TM2
Consecutive helices in polytopic membrane proteins fre-
quently interact [35]. Sequence analysis of TM1 and TM2
helices of tetraspanins reveals a remarkable complemen-
tarity in the distribution of large and small residues at
heptad positions a and d along the helical axis (Figure 3),
suggesting that these residues may interact. To further elu-
cidate the potential for TM1-TM2 interaction, the putative
interface was modeled using a novel algorithm that con-
siders mutational data during each step of a Monte Carlo
simulated annealing cycle (see Methods for details). Specif-
ically, Gly25Leu, Gly32Leu, Gly67Leu and Gly74Leu were
scored as disruptive mutations, while Asn18Ser, Gly77Leu
and Gly80Leu were scored as silent mutations, based on
their effects on protein stability (Figure 5 and data not
shown).
The resulting model predicts left-handed crossing of TM1
and TM2 helices at an angle of +28°. The key element of
the structure is the apposition of bulky and small heptad
position a and d residues, as follows: Gly32-Leu63;
Gly67-Leu29; Gly25-Met70; Gly74-Trp22; Asn18-Gly77;
Ala81-Phe15 (Figure 6). Our model predicts that each of
these residue pairs are in van der Waals contact.
Additionally, two potential H-bonds are predicted in this
model, indicating close packing: Gly67 Cα to Gly25 carb-
onyl oxygen, and Trp22 Cα to Met70 carbonyl oxygen. The
packing is tighter in the ectodomain-proximal portion of
the helices (Figure 6, panel B), as determined by Cα-Cα
distances between interacting residue pairs.
The key elements of the model are corroborated by the
presence of apparently complementary substitutions in
TM1 and TM2 sequences of different tetraspanins (Figure
1, boxed residues). For example, Gly74 is predicted to
interact with Trp22. In 8 of the 10 tetraspanins that con-
tain a substitution for Gly74, a compensatory substitution
occurs at the Trp22 position (Figure 1). Thus, a larger non-
glycine side chain at position 74 may necessitate a less
bulky non-Trp side chain in position 22. Likewise, the
presence of a Cβ at position 25, typically occupied by
glycine, necessitates a non-β-branched amino acid at posi-
tion 70, which is occupied by a β-branched residue in
nearly half of all cases. Indeed, we find that in each of 5
cases in which position 25 contains a Cβ, a leucine residue
Structural model of TM1-TM2 interaction in CD9Figure 6
Structural model of TM1-TM2 interaction in CD9. Shown are space-filling models of CD9 TM1 (panel A), TM2 (panel 
B), and the two helices together (panel C). Small and large residues of heptad positions a and d, which form the crucial con-
tacts between the helices, are shown in green and red, respectively. Asn18 is shown in blue, Leu14 and Phe17 in yellow, and 
Gly80 in light green.Page 9 of 20
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molecular model that suggests Leu70 will pack most favo-
rably against a Cβ at position 25 than a β-branched residue
or a methionine.
Role of TM1 and TM2 heptad motif residues in CD9 
dimerization
To probe CD9 dimerization, we used a cysteine-mediated
cross-linking approach. We established previously a sim-
ple and efficient method for cysteine-mediated cross-link-
ing [25]. After cells are pre-treated with 2-BP for 16–24
hours to expose normally palmitoylated cysteines, the
cysteines can be cross-linked using any of the following
methods: a) Spontaneous oxidation in Brij97 lysates (a
condition that preserves tetraspanin-tetraspanin associa-
tions), b) In situ cross-linking, by pre-lysis oxidation of
cells with Cu2+-phenanthroline (CuP) to promote
disulfide bond formation. c) In situ cross-linking with
thiol-reactive cross-linking agents of defined length (e.g.
DTME, BMB). The first two approaches produce in essence
"zero-length" disulfides, indicative of close proximity of
target cysteines and presumably high specificity of interac-
tion. In contrast, chemical cross-linkers with 6–20 Å
spacer arm may cross-link with higher efficiency, but not
necessarily higher specificity. However, they provide
advantages such as variable membrane permeability, and
potential linkage cleavability. For tetraspanins such as
CD9, membrane-permeable cross-linker DTME (13.3 Å-
long, reducible) provides highly specific and efficient
cross-linking [25]. Here we have used a cysteine cross-
linking strategy, in combination with cysteine-scanning
mutagenesis, to map the residues from TM1 and TM2 con-
tributing to the CD9 dimerization interface.
For subsequent cross-linking experiments using CD9
TM(1+2)-GFP protein, the non-dimerizing form of GFP
was used. This avoids potential GFP-dependent dimeriza-
tion and aggregation that can be observed with wild-type
GFP, especially when fusions with transmembrane pro-
teins are studied [36]. Importantly, the Leu221Lys muta-
tion in GFP prevented aggregation of mutant forms of
CD9 TM(1+2), which was observed with wild-type GFP
fusion (Figure 5). The TM(1+2) fragment of CD9 contains
three native cysteines – Cys9, Cys78 and Cys79. Single-
cysteine mutants of TM(1+2) were constructed, in which
a cysteine was placed at various faces of TM1 or TM2 while
all of the wild-type cysteines were simultaneously
replaced by serines. The mutant proteins were transiently
expressed in RD cells (having little endogenous CD9),
which were then treated for 16–18 hours with 2-BP. To
achieve maximal specificity in cross-linking we used a
"zero-length" agent, CuP.
First, single-cysteine replacements were constructed for
residues Leu14, Phe15, Gly16, Phe17 and Asn18, covering
just over one complete helical turn at the beginning of
TM1. While residue Asn18 is highly conserved, positions
14, 15 and 17 are occupied by bulky hydrophobic resi-
dues in most tetraspanins, whereas position 16 shows less
conservation (Figures 1, 4). All of the single-cysteine
mutants showed diffused pattern of protein localization,
without any signs of aggregation. As shown in Figure 7A,
the highest level of intermolecular cross-linking was
observed for Leu14Cys and Phe17Cys mutants, a lower
level for Phe15Cys and Gly16Cys mutants, and very little
cross-linking for Asn18Cys substitution. These results
indicate that: a) the first two transmembrane domains of
CD9 alone can mediate its dimerization, and b) the g and
c residues of TM1 (e.g. Leu14 and Phe17, Figure 3) are
likely to be part of the intermolecular interface.
Similarly, single-cysteine substitutions were made for res-
idues Gly77, Gly80 and Ala81 in TM2; in addition, pro-
teins carrying a single wild-type cysteine, Cys9, Cys78 or
Cys79, were tested. No protein aggregation was observed
for any of these single-cysteine mutants. As shown in Fig-
ure 7B, the relatively low level of intermolecular cross-
linking of wild-type CD9 TM(1+2)-GFP protein was
enhanced dramatically in single-cysteine TM2 mutants
Gly80Cys and Ala81Cys. The Gly77Cys mutant also had
an elevated level of cross-linking. In contrast, any of the
three native cysteines (9, 78 and 79) produced level of
cross-linking not much greater than the wild-type
TM(1+2) protein. Similar results were obtained with
cysteine-reactive cross-linker BMB (data not shown). Like-
wise, comparable results were obtained with single-
cysteine mutants of untagged, full-length CD9, using CuP
(Figure 7C) as well as DTME cross-linker (data not
shown).
These cross-linking results for TM1 and TM2 are consist-
ent with our model that places residues Leu14, Phe17 and
Gly80 on the same side of the TM1-TM2 pair (Figure 6,
panel C). The strong cross-linking with Leu14Cys,
Phe17Cys and Gly80Cys places the intermolecular inter-
face toward the c and g phases of the TM1 helix, and the g
phase of the TM2 helix, away from its e and f faces con-
taining wild-type cysteines 78 and 79.
Critical residues at the TM1-TM2 interface also affect
dimerization indirectly. To assess specific CD9 dimeriza-
tion, we used a Gly80Cys substitution at the intermolecu-
lar interface for cross-linking. As shown in Figure 8A,
single replacements of conserved heptad residues in posi-
tions 18, 25, 32, 67 and 74 (Asn18Ser, Gly25/32/67/
74→Leu) strongly decreased the cross-linking mediated
by Cys80. The effect was most pronounced for mutations
of residues, Gly32 and Gly67, located in the tightly
packed extracellular end of TM helices (Figure 6). In con-
trast, mutations of residues closer to the cytoplasmic endPage 10 of 20
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Cross-linking of single-cysteine mutants of CD9 protein. GFP fusions of CD9-TM(1+2) protein (panels A and B) or 
untagged full-length CD9 (panel C), and containing wild-type cysteines (Cys9,78,79), a single cysteine at positions indicated, or 
no cysteines (all replaced by Ser) were transiently expressed in human RD cells and cross-linked using CuP. Cell lysates were 
analyzed by Western blotting for GFP (panels A and B) or CD9 (panel C). % dimer is the fraction of dimer in total protein 
material (monomer + dimer), based on densitometry measurements of respective bands.
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Effect of mutations in conserved TM1 and TM2 residues on CD9 cross-linking. RD cells were transfected with con-
structs encoding the following fusion proteins: panel A, CD9 TM(1+2)-GFP, either wild-type or single-cysteine G80C mutant, 
which also carries TM1 and TM2 substitutions indicated; panel B, CD9 TM(1+2)-GFP with no cysteines or wild-type cysteines 
(Cys9,78,79) plus TM1 and TM2 mutations; panel C, full-length CD9-GFP with TM1 and TM2 mutations indicated. The pro-
teins were cross-linked and analyzed by GFP Western as in Figure 7. % dimer was calculated as for Figure 7.
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very little effect on cross-linking.
Relatively low efficiency of intermolecular cross-linking
via native residues Cys9, 78, and 79 (Figures 7B,C) corre-
lates well with the predicted location of Cys78 and 79
away from the dimeric interface (Figure 3), and suggests
that the extramembrane N-terminal part of CD9 (residues
1–13) does not self-associate. We next examined whether
mutations of conserved Asn and Gly residues in TM1 and
TM2 decreased low-level background cross-linking via
native cysteines. As expected, these mutations had
virtually no effect on dimer formation of CD9 TM(1+2)-
GFP (Figure 8B). The level of covalent dimer formed was
not diminished for triple Asn18Ser + Gly25Leu +
Gly32Leu and double Gly67Leu + Gly74Leu mutants,
compared to wild-type TM(1+2) CD9 molecule. Simi-
larly, the same triple and double mutations in the context
of full-length CD9-GFP protein (with six cysteines) pro-
duced wild-type levels of cross-linking (Figure 8C). We
interpret these findings as evidence for at least two types
of associations between CD9 molecules: primary, involv-
ing residues 14, 17 and 80, and dependent on integrity of
conserved heptad residues in TM1 and TM2, and less effi-
cient secondary interactions, probably representing ran-
dom collision events, and independent of the heptad
residues (see Discussion for more details).
TM3 and TM4 cysteine residues in CD9 dimerization
After identifying the roles of conserved TM1 and TM2 res-
idues in CD9 dimerization, we next probed whether resi-
dues proximal to TM domains 3 and 4 are also involved.
To this end, disulfide cross-linking of full-length CD9
molecules containing 3 C-terminal cysteines (87, just
before TM3; 218 and 219 in TM4) or 3 N-terminal
cysteines (9, 78 and 79) was compared (Figure 9). We
found that the C-terminal cysteines were only slightly bet-
ter than N-terminal cysteines with respect to detection of
CD9 dimers. However, markedly more trimers and
tetramers were detected using C-terminal cysteines. Thus,
residues 87, 218 and 219 at TM3 and TM4 in CD9 can
together form contacts across the dimeric interface and
also additional contacts with other neighboring CD9
molecules.
Discussion
Here we provide the first detailed analysis of tetraspanin
protein transmembrane domains. First, we show 1) the
presence of a heptad repeat motif in TM1 and TM2, con-
taining highly conserved Asn and Gly residues, 2) a leu-
cine and glutamate/glutamine-containing heptad motif in
TM3, and 3) high variability and absence of heptad
repeats in TM4 sequences. Second, we provide evidence
for a specific, intramolecular interaction between TM1
and TM2 domains, in which bulky hydrophobic residues
pack against GG7 motif, and present a molecular model
for this interaction. Third, experimental mapping of the
CD9 dimerization interface firmly establishes an
CD9 cross-linking through N- or C-terminal cysteine residuesFigur  9
CD9 cross-linking through N- or C-terminal cysteine 
residues. RD cells were transfected with constructs encod-
ing wild-type CD9 protein, CD9 containing only the three N-
terminal cysteines (Cys9, 78 and 79), or the three C-terminal 
cysteines (Cys87, 218 and 219). Cells were treated with 2-BP 
for 16 hours and lysed in buffer containing 1% Brij97 for 
spontaneous disulfide cross-linking. Cell lysates were ana-
lyzed by CD9 Western. Relative intensity of bands corre-
sponding to CD9 monomers, dimers, trimers and tetramers 
was calculated as a percent fraction of total protein material 
(monomers through tetramers).
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dimeric intermolecular interactions. Fourth, preliminary
evidence is provided to suggest that TM3 and TM4
domains contribute to expansion of CD9 dimers into
higher order multimers.
Conserved residues in TM1 and TM2 of tetraspanins: role 
in intramolecular packing
We hypothesized that the first two transmembrane
domains of tetraspanins might interact with each other
because: a) consecutive TM domains frequently associate
in known protein 3D structures [35], and b) they both
contain a series of highly conserved amino acids – several
Gly residues and an Asn residue (Figure 1). Conserved Gly
residues are a frequent theme in the organization of inter-
acting transmembrane domains. Analysis of 3D helix
packing in polytopic membrane proteins reveals that Gly
residues tend to localize in buried positions, especially at
the helix-helix interfaces and helix crossing points
[37,38]. Due to the absence of a side chain, Gly provides
a flat surface for packing of a side chain from another res-
idue, without loss of side-chain entropy upon interaction.
The most common Gly-containing motif is GxxxG
[39,40]. In glycophorin A (GpA), the major glycoprotein
in erythrocyte cell membranes, Gly79 and Gly83 are part
of the LIxxGVxxGVxxT sequence that promotes
homodimerization of parallel transmembrane α-helixes
[41,42]. In the GpA dimerization motif, Gly residues
allow for tight packing in the right-handed helical
crossing [43]. There are also examples of left-handed
helical crossing in the context of a GxxxG motif [44].
Other membrane proteins that use the GxxxG motif for
homo- or heterodimerization include bacteriophage M13
coat proteins [45], yeast alpha factor receptor [46],
integrin α IIb subunit [47], and ErbB1 receptor tyrosine
kinase [48]. Other small residues, such as Ala and Ser, can
substitute for Gly in this motif [49].
A protein motif in which Gly residues are separated by 6
other residues (GG7) is also common in transmembrane
helices, especially in transporter/channel-like membrane
proteins [50]. However, the structural features associated
with this motif are not well known. In particular, it is
unclear whether left-handed GG7 heptad repeat motif (as
opposed to the "classic" right-handed GxxxG motif) can
drive membrane helix association. In a recent work
addressing this issue, Lear et al. [51] showed that a syn-
thetic peptide containing Gly at heptad positions a and d
could self-associate in vitro, likely in an antiparallel orien-
tation. Heptad repeats containing conserved Gly residues
occur in TM domains of α and β chains of MHC class II
proteins, and mutations of the Gly residues disrupt the αβ
heterodimer [52]. These examples demonstrate that Gly-
based heptad motifs may be used for both intra- and inter-
molecular associations.
In this work, we identified a highly conserved GG7 motif
in the first two tetraspanin TM domains. The GG7
sequence in tetraspanins is a part of a larger motif that also
includes a conserved Asn residue in TM1 (NGG7) and an
Ala/Ser/Thr residue in TM2 (GGA7). The seven-residue
periodicity of these motifs strongly suggests their involve-
ment in left-handed coiled coil packing reminiscent of the
leucine zipper, rather than right-handed packing of the
GpA-like GxxxG motif. For antiparallel helices, the left-
handed crossing is in fact predominant over the right-
handed in known TM domain structures [44].
In our model, heptad Gly residues in NGG7 and GGA7
sequences provide specific packing between antiparallel
tetraspanin TM1 and TM2 helices by allowing tight van
der Waals interactions with large hydrophobic residues
(Figure 6). Highly efficient packing of bulky side chains
against glycine residues is observed in known transmem-
brane protein 3D structures [38,53,54]. An example
includes packing of helices M1 and M2 in potassium
channel KcsA, where Val91 in M2 is paired with Gly43 in
M1, and Leu36 in M1 contacts Ala98 and Gly99 in helix
M2 [54,55]. In addition to facilitating helix-helix packing,
Gly residues frequently provide additional CαH...O
hydrogen bonds between two helices [44]. In our model,
two Cα-backbone carbonyl H-bonds are predicted –
between residues Gly27-Gly67, and Trp22-Met70.
Although polar and charged amino acid residues (such as
Asn in the TM1 heptad motif) are infrequent in trans-
membrane domains, they are functionally important.
Polar residues such as glutamine, glutamic acid, aspartic
acid and asparagine can promote strong oligomerization
of model membrane-associated helices [56-58]. Ruan et
al. [59] used asparagine scanning mutagenesis to probe
the interface of self-associating polyleucine helices by
detecting their enhanced self-interaction in vitro and in the
E. coli-based ToxR assay. Thus, a hydrogen bond in an
apolar environment can result in strong, though not nec-
essarily specific, association of transmembrane helices. In
fact, mutations to polar residues in transmembrane pro-
teins are commonly associated with disease [60]. Because
of this potential for non-specific interactions, polar resi-
dues tend to localize at buried positions in TM domains.
In our case, the conserved Asn18 residue in CD9 is pre-
dicted to be a part of the TM1-TM2 interface, though our
model does not predict any electrostatic interaction
between Asn18 and TM2 (Figure 6). Consistently, substi-
tution such as Asn18Tyr (and Gly77Leu) in TM(1+2)-GFP
protein was not destabilizing as analyzed by protein
aggregation. Curiously, the full-length Asn18Ser CD9
migrated slightly slower on SDS-PAGE gel (data not
shown), suggesting that Asn18 does play a role in main-
taining conformation of the molecule. The Asn18CysPage 14 of 20
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cross-linking (Figure 7A), supporting the proposed loca-
tion of this residue at the intramolecular interface. It is
tempting to speculate that the "pocket" between TM1 and
TM2 lined by Asn18 and Gly77 might be important for
accommodating palmitate moieties that target Cys78 and
Cys79 residues, and/or important for access by the puta-
tive palmitoyl transferase to those residues. Understand-
ing the exact role of these highly conserved Asn18 and
Gly77 residues in tetraspanins awaits further
investigation.
In summary, we identified conserved glycine residues of
TM1 and TM2 of tetraspanins as key elements required for
intramolecular packing. Mutations of these key residues
(Gly25, Gly32, Gly67 and Gly74 in CD9) resulted in pro-
tein destabilization and aggregation. There is ample evi-
dence in the literature for mutations in transmembrane
proteins that lead to protein destabilization, misassembly
and pathologic conditions [61]. Thus, we have identified
conserved heptad Gly residues in TM1 and TM2 of tet-
raspanins as plausible targets of destabilizing mutations
with potential functional consequences.
Intermolecular interactions in tetraspanins
Tetraspanin CD9 forms mostly homodimers, but also a
low level of heterodimers with CD81 and CD151 [25].
Thus, mapping the dimerization interface is an important
next step in structure-function analysis of tetraspanins.
Disulfide-mediated cross-linking, often in combination
with cysteine-scanning mutagenesis, is a common strategy
to probe oligomerization or intersubunit interactions of
transmembrane proteins such as histidine kinase EnvZ
[62], M(3) muscarinic acetylcholine receptor [63], E. coli
lactose permease [64], synaptobrevin [65], integrins [66]
and many others. In tetraspanins such as CD9, mem-
brane-proximal cysteine residues are especially useful tar-
gets for disulfide trapping, as their linkage can be
enhanced by pre-treating cells with 2-BP. While the ability
of wild-type cysteines in CD9 to be cross-linked may
indicate that they are close to the dimerization interface,
more precise mapping was achieved here using cysteine-
scanning mutagenesis.
Our data clearly identify regions, near the cytoplasmic
face of TM1 and TM2, important for dimerization.
Intermolecular zero-length cross-linking was highest
when single cysteines were placed in positions 14, 17, 77,
80 and 81 in TM(1+2)-GFP molecule, or at positions 77,
80 or 81 in the full-length CD9 protein. Positions 14, 17
and 80 are distinct from the intramolecular interface and
are on the same side of the TM1-TM2 pair (Figure 6).
Thus, they are well-positioned to participate in an interac-
tion with another molecule. At the same time, the model
predicts that wild-type cysteines (Cys78, 79), which do
not yield very efficient zero-length cross-linking, are on
the other side of TM1-TM2 pair.
While using the cysteine at position 80 as the dimeric
interface probe, mutations of conserved residues in TM1
and TM2 (especially Gly32 and Gly67 to Leu) clearly
reduced intermolecular cross-linking. We do not suggest
that those residues are directly involved in intermolecular
interaction. Rather, we propose that destabilization of the
intramolecular TM1-TM2 interaction by Gly to Leu substi-
tutions (discussed above) causes an overall conforma-
tional change that reduces dimer formation.
An Ala81Leu mutation did not reduce cross-linking via
Cys80, even though single-cysteine Ala81Cys molecules
themselves produced a high level of cross-linking. These
results, together with data on Gly32Leu and Gly67Leu
mutations, are consistent with our model predicting that
helices 1 and 2 interact more tightly near the extracellular
end and less at the cytoplasmic end. This would give more
flexibility to a cysteine at position 81 and also limit the
effect of an Ala81Leu mutation. Location of this residue at
the membrane/cytoplasmic border could also make it
more accessible to CuP reagent as compared to residues
buried in TM domain, thus elevating the efficiency of
disulfide formation of the Ala81Cys mutant.
Multiple interfaces in tetraspanin molecules
In the full-length CD9 molecules, the 3 C-terminal
cysteines (Cys87, 218 and 219) located at or in TM3 and
TM4 promoted efficient dimer and even more efficient
oligomer formation compared to the 3 N-terminal
cysteines (Figure 9). Cys87 alone can be used to capture
CD9 dimers [25]. These results suggest the existence of
two dimeric interfaces in CD9 molecule – the TM 1-2/1-2
interface and the TM 3-4/3-4 interface (Figure 10). In a
TM(1+2) molecule, the destabilization of 1–2 interaction,
e.g. by Gly→Leu mutations, would affect the 1-2/1-2
interface, as discussed above. However, these mutations
would not interfere with the 3-4/3-4 interface in a full-
length molecule, which includes Cys87, 218 and 219.
Thus, cross-linking of full-length molecules, containing
all 6 cysteine residues, would be unaffected, as seen in Fig-
ure 8C. Furthermore, wild-type Cys9, Cys78 and Cys79
are apparently not at the primary 1-2/1-2 interface. Their
relative inefficiency in cross-linking CD9 TM(1+2) pro-
tein likely reflects weak secondary contacts between the
molecules, or possibly random collision events. Such
events should be independent of mutations in the con-
served Gly residues in TM1 and TM2, as was demonstrated
in Figure 8B. The potential existence of two interfaces in
tetraspanin molecules, 1-2/1-2 and 3-4/3-4, should pro-
vide enhanced flexibility for forming additional intermo-
lecular contacts. Current understanding of tetraspanin
microdomains assumes a few strong, primary homotypicPage 15 of 20
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CD9-CD81, CD151-α3 integrin, CD81-EWI2) that help
bring together various other proteins, forming secondary-
type associations. Such properties of tetraspanins may
bring signaling molecules such as protein kinase C or
phosphatidylinositol 4-kinase to the vicinity of integrins
[67,68].
The organization of the TM3 domain points to a potential
role in protein-protein interactions. A motif of Leu-Leu-
Glu(Gln) spaced 7 residues apart (heptad positions a),
with highly conserved residues in two consecutive posi-
tions d, poses as a likely interaction module. If responsible
for heterologous protein-protein interactions, it would
form another distinct interface of tetraspanin molecule.
Our preliminary data indicate that replacing the Leu and
Glu residues in TM3 of CD9 with Ala has no effect on cell
surface expression of the protein and its dimerization
(data not shown). It remains to be tested if interactions
with other proteins will be affected. Similarly, the TM4
domain may provide additional contributions to lateral
tetraspanin associations. Much higher sequence variabil-
ity, and the lack of a distinct heptad pattern suggests that
TM4 is a major contributor to diversity among tetraspanin
complexes. Structure-function analysis of TM3 and TM4
domains in tetraspanins is the subject of ongoing
investigation.
Conclusion
We have defined the TM1-TM2 intramolecular interface in
tetraspanin CD9, providing evidence for glycines (Gly25
and Gly32 in TM1, Gly67 and Gly74 in TM2) packing
against apposing bulky aliphatic residues. Second, we
mapped an intermolecular CD9 interface (involved in
CD9 homodimer formation) to the vicinity of residues
Leu14 and Phe17 in TM1 and Gly77, Gly80 and Ala81 in
TM2. Finally, we provide preliminary evidence that TM3
and TM4 in CD9 may contribute to a second intermolecu-
A model of the organization of a tetraspanin dimerFigure 10
A model of the organization of a tetraspanin dimer. Two interfaces, the intramolecular TM1/TM2 and intermolecular 
TM1-TM2/TM1-TM2, have been analysed in this work. A third interface, intermolecular TM3-TM4/TM3-TM4, is predicted.
1-2/1-2 Dimer
Interface
(Leu14, Phe17,
Gly80)
1/2
Interface
(Asn18, Gly25,
32, 67, 74)
3-4/3-4
Interface (?)
12
3 4
1 2
34Page 16 of 20
(page number not for citation purposes)
BMC Structural Biology 2005, 5:11 http://www.biomedcentral.com/1472-6807/5/11lar interface. Key CD9 residues involved in intra- and
intermolecular interactions are highly conserved
throughout the tetraspanin family, thus suggesting that
our findings will apply to most tetraspanins.
Methods
Materials
Cell culture reagents were from Invitrogen (Carlsbad, CA).
2-bromopalmitate was from Fluka (Milwaukee, WI), N-
ethylmaleimide (NEM) and 1,10-phenanthroline were
from Sigma-Aldrich (St. Louis, MO), and chemical cross-
linkers dithio-bis-maleimidoethane (DTME) and 1,4-Bis-
maleimidobutane (BMB) were purchased from Pierce
Endogen (Rockford, IL). Triton X-100, protease inhibitor
cocktail and FuGENE 6 transfection reagent were
obtained from Roche (Indianapolis, IN). Restriction
endonucleases and Pfu DNA polymerase were obtained
New England Biolabs (Beverly, MA) and Stratagene
(Carlsbad, CA), respectively. All other chemicals were pur-
chased from Sigma-Aldrich or Fisher Scientific (Pittsburg,
PA).
Sequence analysis
Tetraspanin sequences were obtained from SWISS-PROT
and GenBank databases. Locus designations, accession
numbers and the most commonly used protein names are
summarized in Tables 1 and 2. TM segments were deline-
ated by inspection of hydrophobicity profiles, using data-
base annotations and previous analyses of TM sequences
as a guide ([28], M. Hemler, unpublished), and aligned
manually. Residue numbers in human CD9 sequence are
used a reference point throughout the study.
DNA cloning and mutagenesis
Sequence encoding CD9 protein was cloned into vector
pcDNA3 (Invitrogen, Carlsbad, CA) and pEGFP-N1
(Clontech, Palo Alto, CA), for expression of untagged and
C-terminally GFP-tagged CD9, respectively. pEGFP-N1
encoding CD9 TM(1+2) -GFP fusion protein was con-
structed by subcloning DNA for residues 1–83 of CD9
into HindIII and PstI sites of the vector; to introduce the
PstI site, codon GTG for Val82 was changed to CTG (cod-
ing for Ala). In the resulting fusion protein, there is a 13-
amino acid linker (with no cysteines) between CD9 and
GFP. To minimize the low inherent ability of GFP to
homodimerize, which could potentially influence the
Table 1: Human tetraspanin sequences analyzed in this study.
SWISS-PROT locus name Accession number Protein name(s)
TSN1_HUMAN O60635 NET-1, Tspan-1
CD82_HUMAN P27701 CD82 antigen NM_030927
CD37_HUMAN P11049 CD37 antigen
CD53_HUMAN P19397 CD53 antigen
T4S7_HUMAN O14817 NAG-2, Tspan-4
TNE5_HUMAN O75954 NET-5
BAB55318 AK027715 -
TSN2_HUMAN O60636 Tspan-2
T4S9_HUMAN P62079 NET-4, Tspan-5
TM4B_HUMAN Q9UKR8 TM4B
- NM_030927 -
C151_HUMAN P48509 CD151 antigen, PETA-3
CD9_HUMAN P21926 CD9 antigen, p24, MRP-1
CD81_HUMAN P60033 CD81 antigen, TAPA-1
T4S3_HUMAN P19075 CO-029 antigen
T4S8_HUMAN O60637 Tspan-3, TM4-A
T412_HUMAN O95859 NET-2
SAS_HUMAN Q12999 Sarcoma amplified sequence (SAS)
T413_HUMAN O95857 NET-6
TNE7_HUMAN O95858 NET-7
CD63_HUMAN P08962 CD63 antigen, LAMP-3
T4S2_HUMAN P41732 A15, TALLA-1, CD231 antigen
T4S6_HUMAN O43657 Tspan-6, TM4-D
OCSP_HUMAN Q9H1Z9 Oculospanin (Ocsp)
UPKA_HUMAN O00322 Uroplakin Ia (UPIa)
UPKB_HUMAN O75841 Uroplakin Ib (UPIb)
RDS_HUMAN P23942 Peripherin, Retinal degeneration slow protein (RDS)
ROM1_HUMAN Q03395 Rod outer segment membrane protein-1 (ROM-1)Page 17 of 20
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mutant, Leu221→Lys [34], for cross-linking experiments.
Mutations were introduced in full-length and TM(1+2)
CD9 proteins by a PCR-based strategy using mutagenic
primers and Pfu DNA polymerase. All mutations were
confirmed by DNA sequencing.
Protein expression, microscopy, cysteine disulfide cross-
linking and Western blotting
DNA constructs encoding TM(1+2)-GFP or full-length
CD9 proteins were transfected into human rhabdomyosa-
rcoma RD cells using the FuGENE 6 reagent. Cells express-
ing GFP fusion proteins were analysed by fluorescence
microscopy 18–28 hours post-transfection. Images were
captured using Spot 1.4.0 camera (Diagnostic
Instruments, Sterling Heights, MI) attached to Nikon
Eclipse TE300 microscope.
For experiments involving cysteine-mediated cross-link-
ing, cells were treated with 50 µM 2-BP starting 24–26
hours post-transfection and continuing for 16–18 hours.
Cross-linking was carried out by incubating cells in HBSM
buffer (25 mM Hepes-NaOH, pH 7.2, 150 mM NaCl, 2
mM MgCl2) containing either a) 0.6 mM CuSO4 and 1.8
mM 1,10-phenanthroline (CuP complex) or b) 0.2 mg/ml
homobifunctional cysteine-reactive cross-linker (e.g.
DTME), diluted from fresh 10 mg/ml solution in DMSO.
After incubation for 10–15 minutes (with CuP) or 30–45
minutes (with cross-linker), cells were washed twice for
10 minutes with HBSM containing 10 mM NEM to block
residual free cysteines. Cells were lysed in HBSM
containing 1% Triton X-100, 0.1% SDS and a cocktail of
protease inhibitors with 1 mM EDTA at 4°C for 45–60
minutes. Cell lysate was clarified by centrifugation at
14,000 × g for 15 minutes, an aliquot was removed, and
proteins from it were precipitated by addition of trichlo-
roacetic acid to 10% on ice followed by centrifugation at
14,000 × g for 10 minutes. After two washes with ice-cold
acetone, protein pellet was solubilized in SDS-PAGE sam-
ple buffer without a reducing agent (50 mM Tris-HCl, pH
6.8, 1% SDS, 8% glycerol).
In some experiments, CD9 protein was immunoprecipi-
tated using monoclonal antibody Alb6 (Immunotech,
Marseille, France). Proteins were separated by SDS-PAGE
and analyzed by Western blotting using monoclonal anti-
body JL-8 (Clontech) for GFP or Alb6 for CD9. Bands
from X-ray films were quantitated using GeneTools™ soft-
ware from Syngene (Frederick, MD).
Modeling of TM1-TM2 interaction
An atomic model of the CD9 TM1-TM2 dimer was con-
structed with a Monte Carlo-simulated annealing (MCSA)
algorithm [69]. Two idealized α-helices corresponding to
TM1 residues Tyr12 through Leu35 and TM2 residues
Gly59 through Val82 were docked with six orthogonal
parameters: three rigid body translations and three rota-
tions. During each step of a MCSA cycle, there was an
equal probability of changing either one parameter or all
six parameters to random values. A conformation's energy
was calculated in vacuo with the AMBER united-atom force
field for van der Waals interactions [70]. The van der
Waals term was modified as described by Kuhlman and
Baker [71]. If a structure had favorable dimerization
energy, the energies of select mutants were calculated.
Structures were selected with a novel scoring function that
maximizes the Boltzmann probability of dimerization for
silent mutations while minimizing the probability for dis-
ruptive mutations. Asn18Ser, Gly77Leu, and Gly80Leu
were scored as silent mutations while Gly25Leu,
Gly32Leu, Gly67Leu, and Gly74Leu were considered to be
disruptive. Each MCSA cycle consisted of 50,000 steps
with an exponential temperature decay from 10,000 to 10
K.
Ten MCSA cycles through global sample space were used
to restrict the search area. Parameters were restricted to ±
Table 2: Vertebrate CD9 orthologs analyzed in this study.
Organism SWISS-PROT or GenBank locus name Accession number
Homo sapiens (Human) CD9_HUMAN P21926
Cercopithecus aethiops (African green monkey) CD9_CERAE P30409
Sus scrofa (Pig) CD9_PIG Q8WMQ3
Bos taurus (Cow) CD9_BOVIN P30932
Felis catus (Cat) CD9_FELCA P40239
Rattus norvegicus (Norway rat) CD9_RAT P40241
Mus musculus (House mouse) CD9_MOUSE P40240
Gallus gallus (Chicken) NP_990093 (GenBank) NP_990093
Petromyzon marinus (Sea lamprey) AAN64299 (GenBank) AAN64299
Danio rerio (Zebrafish) AAH59691 (GenBank) AAH59691Page 18 of 20
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within 10 kcal of the best structure. MCSA cycles were
repeated as described above with additional optimization
of χ values: rotamers at the protein-protein interface were
optimized with Dead End Elimination [72], and χ values
were further optimized with Monte Carlo. All MCSA
cycles converged upon structures that were within a root
mean squared deviation (RMSD) of 1.5 Å with the best
structure, and structures that scored within 5 kcal of the
best score had an RMSD of less than 0.5 Å with the best
structure.
List of abbreviations
2-BP, 2-bromopalmitate; CuP, Cu2+-phenanthroline;
DTME, dithio-bis-maleimidoethane; LEL, large extracellu-
lar loop; NEM, N-ethylmaleimide; TM, transmembrane
(domain).
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